BR112015012497A2 - combinações farmacêuticas - Google Patents

combinações farmacêuticas

Info

Publication number
BR112015012497A2
BR112015012497A2 BR112015012497A BR112015012497A BR112015012497A2 BR 112015012497 A2 BR112015012497 A2 BR 112015012497A2 BR 112015012497 A BR112015012497 A BR 112015012497A BR 112015012497 A BR112015012497 A BR 112015012497A BR 112015012497 A2 BR112015012497 A2 BR 112015012497A2
Authority
BR
Brazil
Prior art keywords
pharmaceutically acceptable
combination
protein kinase
pharmaceutical combinations
acceptable salt
Prior art date
Application number
BR112015012497A
Other languages
English (en)
Other versions
BR112015012497A8 (pt
BR112015012497B1 (pt
Inventor
Emery Caroline
Porter Dale
Tan Lujian
Yerramilli- Rao Padmaja
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BR112015012497A2 publication Critical patent/BR112015012497A2/pt
Publication of BR112015012497A8 publication Critical patent/BR112015012497A8/pt
Publication of BR112015012497B1 publication Critical patent/BR112015012497B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo "combinações farmacêuticas". uma combinação farmacêutica compreendendo: (a) um composto inibidor de proteína quinase c (pkc), ou um sal farmaceuticamente aceitável do mesmo, e (b) pelo menos um inibidor de proteína quinase ativado por mitógeno (mek) ou um sal farmaceuticamente aceitável do mesmo, e, opcionalmente, um carreador farmaceuticamente aceitável, para administração simultânea, separada ou sequencial; as utilizações de tal combinação no tratamento de doenças proliferativas; e métodos de tratamento de um sujeito que sofre de uma doença proliferativa que compreende a administração de uma quantidade terapeuticamente eficaz de tal combinação.
BR112015012497-6A 2012-11-29 2013-11-26 Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial BR112015012497B1 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261731174P 2012-11-29 2012-11-29
US61/731,174 2012-11-29
US201261731555P 2012-11-30 2012-11-30
US61/731,555 2012-11-30
US201361755520P 2013-01-23 2013-01-23
US61/755,520 2013-01-23
PCT/US2013/071852 WO2014085381A1 (en) 2012-11-29 2013-11-26 Pharmaceutical combinations

Publications (3)

Publication Number Publication Date
BR112015012497A2 true BR112015012497A2 (pt) 2017-07-11
BR112015012497A8 BR112015012497A8 (pt) 2019-10-01
BR112015012497B1 BR112015012497B1 (pt) 2022-05-17

Family

ID=49753513

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015012497-6A BR112015012497B1 (pt) 2012-11-29 2013-11-26 Combinações e composições farmacêuticas, seus usos, preparação combinada, e embalagem comercial

Country Status (17)

Country Link
US (1) US9446043B2 (pt)
EP (1) EP2925366B1 (pt)
JP (1) JP6437444B2 (pt)
CN (1) CN104812415A (pt)
AU (1) AU2013352379B2 (pt)
BR (1) BR112015012497B1 (pt)
CA (1) CA2892578C (pt)
DK (1) DK2925366T3 (pt)
ES (1) ES2669248T3 (pt)
HK (1) HK1215789A1 (pt)
HU (1) HUE037618T2 (pt)
NZ (1) NZ708802A (pt)
PL (1) PL2925366T3 (pt)
RU (1) RU2674995C2 (pt)
TR (1) TR201806682T4 (pt)
UA (1) UA115250C2 (pt)
WO (1) WO2014085381A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201904851D0 (en) 2019-04-05 2019-05-22 Katholieke Univ Leven Melanoma treatment
US11086278B2 (en) 2019-08-29 2021-08-10 Inventus Holdings, Llc Adaptive system monitoring using incremental regression model development
EP4322953A1 (en) * 2021-04-15 2024-02-21 Ideaya Biosciences, Inc. Combination therapy comprising a pkc inhibitor and a mek inhibitor
WO2024044774A2 (en) * 2022-08-26 2024-02-29 Ideaya Biosciences, Inc. Methods of treating uveal melanoma with a pkc inhibitor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489608A (en) 1989-12-21 1996-02-06 Goedecke Aktiengesellschaft Indolocarbazole derivatives and the use thereof
US5475085A (en) 1991-02-07 1995-12-12 Molecumetics, Ltd. Conformationally restricted mimetics of beta turns and beta bulges and peptides containing the same
HU219709B (hu) 1993-12-07 2001-06-28 Eli Lilly And Co. Proteinkináz C gátló hatású kondenzált indolszármazékok, eljárás előállításukra, és az ezeket tartalmazó gyógyászati készítmények
DK0817627T3 (da) 1993-12-23 2005-06-06 Lilly Co Eli Inhibitorer af proteinkinase C
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
HU226821B1 (en) 1995-11-20 2009-11-30 Lilly Co Eli The mesylate salt of a macrocyclic bis-indolyl-maleimide derivative, process for its preparation, use thereof and pharmaceutical compositions containing the same
US6960614B2 (en) 2000-07-19 2005-11-01 Warner-Lambert Company Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
US6645970B2 (en) 2000-11-07 2003-11-11 Novartis Ag Indolylmaleimide derivatives
EP1337527B1 (en) 2000-11-07 2009-10-14 Novartis AG Indolylmaleimide derivatives as protein kinase c inhibitors
ES2407849T3 (es) * 2002-03-13 2013-06-14 Array Biopharma, Inc. Derivados de bencimidazol alquilados N3 como inhibidores de MEK
TWI324064B (en) 2002-04-03 2010-05-01 Novartis Ag Indolylmaleimide derivatives
US6930093B2 (en) * 2003-07-10 2005-08-16 Valeant Research & Development Use of ribofuranose derivatives against inflammatory bowel diseases
RU2364596C2 (ru) 2004-06-11 2009-08-20 Джапан Тобакко Инк. ПРОИЗВОДНЫЕ 5-АМИНО-2,4,7-ТРИОКСО-3,4,7,8-ТЕТРАГИДРО-2Н-ПИРИДО[2,3-d] ПИРИМИДИНА, ОБЛАДАЮЩИЕ ПРОТИВООПУХОЛЕВОЙ АКТИВНОСТЬЮ
MY149960A (en) 2005-05-18 2013-11-15 Array Biopharma Inc 4-(phenylamino)-6-oxo-1,6-dihydropyridazine-3-carboxamide derivatives as mek inhibitors for the treatment of hyperproliferative diseases
KR20080023732A (ko) 2005-07-11 2008-03-14 노파르티스 아게 인돌릴말레이미드 유도체

Also Published As

Publication number Publication date
AU2013352379B2 (en) 2018-09-06
DK2925366T3 (en) 2018-06-06
RU2674995C2 (ru) 2018-12-14
CA2892578C (en) 2021-01-12
AU2013352379A1 (en) 2015-06-11
RU2015124954A (ru) 2017-01-11
JP6437444B2 (ja) 2018-12-12
ES2669248T3 (es) 2018-05-24
US9446043B2 (en) 2016-09-20
CA2892578A1 (en) 2014-06-05
JP2016501222A (ja) 2016-01-18
BR112015012497A8 (pt) 2019-10-01
TR201806682T4 (tr) 2018-06-21
WO2014085381A1 (en) 2014-06-05
NZ708802A (en) 2019-09-27
CN104812415A (zh) 2015-07-29
UA115250C2 (uk) 2017-10-10
EP2925366B1 (en) 2018-02-21
PL2925366T3 (pl) 2018-08-31
US20150306101A1 (en) 2015-10-29
HUE037618T2 (hu) 2018-09-28
EP2925366A1 (en) 2015-10-07
BR112015012497B1 (pt) 2022-05-17
HK1215789A1 (zh) 2016-09-15

Similar Documents

Publication Publication Date Title
BR112016012506A8 (pt) combinações farmacêuticas, seus usos, e uso de um portador de dados
MX2019004616A (es) Métodos de uso de indazol-3-carboxamidas y su uso como inhibidores de la ruta de señalización de wnt/b-catenina.
BR112015029512A2 (pt) derivados de pirazolopirrolidina e seu uso no tratamento de doenças
MX2015001122A (es) Combinaciones farmaceuticas de un inhibidor de cdk4/6 y un inhibidor de b-raf.
BR112019005046A2 (pt) combinações terapêuticas compreendendo um inibidor de raf e um inibidor de erk
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
WO2015054619A8 (en) Use of a pcsk9 inhibitor to treat hyperlipidemia
MX2019012884A (es) Terapia de combinacion.
NZ703940A (en) Pharmaceutical combinations comprising a b-raf inhibitor, an egfr inhibitor and optionally a pi3k-alpha inhibitor
BR112013029246A2 (pt) 4-amino-5-flúor-3-[6- (4-metilpiperazin- 1 - il) - 1h - benzimidazol - 2 - il] - 1h - quinolin-2-ona para uso no tratamento de carcinoma adenoide cístico
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
BR112014027010A2 (pt) uso de laquinimod de alta dose para tratamento de esclerose múltipla
WO2016090024A3 (en) Combination therapy for treatment of cancer
BR112014004587A2 (pt) combinações sinérgicas de inibidores de pi3k- e de mek
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
BR112015010039A2 (pt) tratamento de câncer com pomalidomida em um individuo com disfunção renal
AR093182A1 (es) Metodo para tratar el sobrepeso o la obesidad
IN2015DN00528A (pt)
BR112018073553A2 (pt) medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato.
BR112015012497A2 (pt) combinações farmacêuticas
BR112017021583A2 (pt) métodos para o tratamento de transtornos inflamatórios
BR112012020377A8 (pt) utilização de um ou mais selecionado do grupo constituído por um composto da fórmula (i), uma mistura racêmica-diastereomérica e um isômero óptico do referido composto, e um sal farmaceuticamente aceitável e uma pródroga do mesmo, método, composição farmacêutica e kit para tratamento de caquexia e embalagem comercial
BR112014030288A8 (pt) composição farmacêutica, uso da mesma, e, uso de metanossulfonilacetonitrila
MX2021007324A (es) Terapia oral con acido 6,8-bis-benciltio-octanoico.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO EM FUNCAO DA REVOGACAO DO ART. 229-C DA LEI NO 9.279, DE 1996, POR FORCA DA LEI NO 14.195, DE 2021

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 26/11/2013, OBSERVADAS AS CONDICOES LEGAIS